Literature DB >> 25355653

Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample.

Ines Buchholz1, Kirsten Thielker, You-Shan Feng, Peter Kupatz, Thomas Kohlmann.   

Abstract

PURPOSE: To compare measurement properties and sensitivity to change of the standard version of the EQ-5D (3L) with a newly developed 5-level version (5L) in a multicenter sample of German rehabilitation inpatients (n = 230).
METHODS: Rehabilitation patients (n = 114 orthopedic, n = 54 psychosomatic, n = 62 rheumatic) were asked to complete both versions of the EQ-5D and several other questionnaires at the beginning of, the end of and 3 month after inpatient rehabilitation. 3L and 5L were compared regarding missing values, ceiling effects, redistribution properties, informativity and sensitivity to change.
RESULTS: There were nearly no missing values in both questionnaires. Ceiling effects were 1.6 % points to 16.4 % points lower on average for the 5L. For psychosomatic patients, ceiling effects for 5L were as high as in the general German population. Absolute informativity (mean 5L: 1.76, 3L: 1.06) and relative informativity (5L: 0.76, 3L: 0.67) were both higher for 5L. 5L could better detect both positive and negative health changes in most dimensions and patient samples. Overall, patients made better use of the response levels of the 5L. Average proportion of inconsistent responses between 3L and 5L was 6.1 %.
CONCLUSIONS: Cross-sectionally and longitudinally, 5L was associated with an improved ability to detect health changes over time, reduced ceiling effects, and improved discriminatory power. Overall, these findings were in line with previous study outcomes, although differing in magnitude. Since the sample size is moderate and generalizability of the reported results is unclear, further comparisons in other patient populations will be informative and should be encouraged.

Entities:  

Mesh:

Year:  2014        PMID: 25355653     DOI: 10.1007/s11136-014-0838-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

1.  On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation.

Authors:  C B Terwee; F W Dekker; W M Wiersinga; M F Prummel; P M M Bossuyt
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

2.  [The version 2.0 of the SF-36 Health Survey: results of a population-representative study].

Authors:  Matthias Morfeld; Monika Bullinger; Juliane Nantke; Elmar Brähler
Journal:  Soz Praventivmed       Date:  2005

3.  Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

Authors:  A Simon Pickard; Maria C De Leon; Thomas Kohlmann; David Cella; Sarah Rosenbloom
Journal:  Med Care       Date:  2007-03       Impact factor: 2.983

4.  The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population.

Authors:  Andreas Hinz; Thomas Kohlmann; Yve Stöbel-Richter; Markus Zenger; Elmar Brähler
Journal:  Qual Life Res       Date:  2013-08-07       Impact factor: 4.147

5.  Comparing the standard EQ-5D three-level system with a five-level version.

Authors:  Mathieu F Janssen; Erwin Birnie; Juanita A Haagsma; Gouke J Bonsel
Journal:  Value Health       Date:  2008 Mar-Apr       Impact factor: 5.725

6.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Authors:  Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard
Journal:  Value Health       Date:  2012-05-24       Impact factor: 5.725

7.  Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods.

Authors:  M F Janssen; E Birnie; G J Bonsel
Journal:  Qual Life Res       Date:  2008-03-05       Impact factor: 4.147

8.  Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.

Authors:  Luciana Scalone; Roberta Ciampichini; Stefano Fagiuoli; Ivan Gardini; Francesco Fusco; Laura Gaeta; Anna Del Prete; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Qual Life Res       Date:  2012-11-29       Impact factor: 4.147

9.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

10.  The development of new research methods for the valuation of EQ-5D-5L.

Authors:  Nancy J Devlin; Paul F M Krabbe
Journal:  Eur J Health Econ       Date:  2013-07
View more
  20 in total

1.  Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Authors:  Fanni Rencz; Peter L Lakatos; László Gulácsi; Valentin Brodszky; Zsuzsanna Kürti; Szilvia Lovas; János Banai; László Herszényi; Tamás Cserni; Tamás Molnár; Márta Péntek; Károly Palatka
Journal:  Qual Life Res       Date:  2018-09-17       Impact factor: 4.147

2.  Psychometric performance assessment of Malay and Malaysian English version of EQ-5D-5L in the Malaysian population.

Authors:  Asrul Akmal Shafie; Annushiah Vasan Thakumar; Ching Jou Lim; Nan Luo
Journal:  Qual Life Res       Date:  2018-10-13       Impact factor: 4.147

3.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.

Authors:  Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek
Journal:  Qual Life Res       Date:  2017-09-05       Impact factor: 4.147

4.  Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness.

Authors:  Amaia Bilbao; Lidia García-Pérez; Juan Carlos Arenaza; Isidoro García; Gloria Ariza-Cardiel; Elisa Trujillo-Martín; Maria João Forjaz; Jesús Martín-Fernández
Journal:  Qual Life Res       Date:  2018-07-05       Impact factor: 4.147

5.  Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China.

Authors:  Jie Jiang; Yanming Hong; Tiantian Zhang; Zhihao Yang; Tengfei Lin; Zhuoru Liang; Peiyao Lu; Lishun Liu; Binyan Wang; Yongmei Xu; Nan Luo
Journal:  Qual Life Res       Date:  2021-04-05       Impact factor: 4.147

6.  EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.

Authors:  Mihir Gandhi; Marcus Ang; Kelvin Teo; Chee Wai Wong; Yvonne Chung-Hsi Wei; Rachel Lee-Yin Tan; Mathieu F Janssen; Nan Luo
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

7.  Development of the web-based Spanish and Catalan versions of the Euroqol 5D-Y (EQ-5D-Y) and comparison of results with the paper version.

Authors:  Noemí Robles; Luis Rajmil; Dolors Rodriguez-Arjona; Marta Azuara; Francisco Codina; Hein Raat; Ulrike Ravens-Sieberer; Michael Herdman
Journal:  Health Qual Life Outcomes       Date:  2015-06-03       Impact factor: 3.186

8.  A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D.

Authors:  Ines Buchholz; Mathieu F Janssen; Thomas Kohlmann; You-Shan Feng
Journal:  Pharmacoeconomics       Date:  2018-06       Impact factor: 4.981

9.  Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.

Authors:  Iftekhar Khan; Steve Morris; Nora Pashayan; Bashir Matata; Zahid Bashir; Joe Maguirre
Journal:  Health Qual Life Outcomes       Date:  2016-04-12       Impact factor: 3.186

10.  Psychometric properties and population norms of the positive mental health instrument in a representative multi-ethnic Asian population.

Authors:  Janhavi Ajit Vaingankar; Mythily Subramaniam; Linda Wei Lin Tan; Edimansyah Abdin; Wei Yen Lim; Hwee Lin Wee; Siow Ann Chong; Rob Martinus van Dam
Journal:  BMC Med Res Methodol       Date:  2018-03-15       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.